BLUE KNIGHT™ is a joint initiative by Johnson & Johnson Innovation – JLABS and BARDA, the biomedical research authority of the U.S. Department of Health. Its QuickFire Challenge invited innovators from around the world to submit technologies to prepare for known and unknown infectious disease threats.
One of the focuses of the call was the manufacturing of vaccines and treatments with a longer shelf life and less dependence on the cold chain, a challenge directly related to NanoFreeze technology to preserve biologics between 2°C and 8°C without electricity.
The winners share a pool of up to USD 200,000 and gain access to a residency in the JLABS network with mentorship from experts at Johnson & Johnson and BARDA.
